Javasky E, Shamir I, Gandhi S, et al. Study of mitotic chromatin supports a model of bookmarking by histone modifications and reveals nucleosome deposition patterns. Genome Res. 2018;28(10):1455-1466. doi:10.1101/gr.230300.117
Fass DM, Reis SA, Ghosh B, et al. Crebinostat: a novel cognitive enhancer that inhibits histone deacetylase activity and modulates chromatin-mediated neuroplasticity. Neuropharmacology. 2013;64:81-96. doi:10.1016/j.neuropharm.2012.06.043
Ferguson BS, Harrison BC, Jeong MY, et al. Signal-dependent repression of DUSP5 by class I HDACs controls nuclear ERK activity and cardiomyocyte hypertrophy. Proc Natl Acad Sci U S A. 2013;110(24):9806-11. doi:10.1073/pnas.1301509110
Wilson AJ, Holson E, Wagner F, et al. The DNA damage mark pH2AX differentiates the cytotoxic effects of small molecule HDAC inhibitors in ovarian cancer cells. Cancer Biol Ther. 2011;12(6):484-93. doi:10.4161/cbt.12.6.15956
Schroeder FA, Chonde DB, Riley MM, et al. FDG-PET imaging reveals local brain glucose utilization is altered by class I histone deacetylase inhibitors. Neurosci Lett. 2013;550:119-24. doi:10.1016/j.neulet.2013.06.016
Koeller KM, Haggarty SJ, Perkins BD, et al. Chemical genetic modifier screens: small molecule trichostatin suppressors as probes of intracellular histone and tubulin acetylation. Chem Biol. 2003;10(5):397-410.
Kemp MM, Wang Q, Fuller JH, et al. A novel HDAC inhibitor with a hydroxy-pyrimidine scaffold. Bioorg Med Chem Lett. 2011;21(14):4164-9. doi:10.1016/j.bmcl.2011.05.098
Ott CJ, Wu CJ. HDAC Inhibitors Finally Open Up: Chromatin Accessibility Signatures of CTCL. Cancer Cell. 2017;32(1):1-3. doi:10.1016/j.ccell.2017.06.008
Wong JC, Hong R, Schreiber SL. Structural biasing elements for in-cell histone deacetylase paralog selectivity. J Am Chem Soc. 2003;125(19):5586-7. doi:10.1021/ja0341440
Taunton J, Hassig CA, Schreiber SL. A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science. 1996;272(5260):408-11.